Zandelisib (ME401; ME-401) is a novel, potent, orally bioavailable, and selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor with potential anticancer activity. It inhibits PI3Kδ with an IC50 of 3.5 nM. Zandelisib is being developed in a phase II clinical trial for the treatment of follicular lymphoma and other B-cell malignancies.

纯度：≥98%

CAS：1401436-95-0